EA201692031A1 - Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций - Google Patents

Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций

Info

Publication number
EA201692031A1
EA201692031A1 EA201692031A EA201692031A EA201692031A1 EA 201692031 A1 EA201692031 A1 EA 201692031A1 EA 201692031 A EA201692031 A EA 201692031A EA 201692031 A EA201692031 A EA 201692031A EA 201692031 A1 EA201692031 A1 EA 201692031A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bacterial infections
respect
pharmaceutical composition
chronic bacterial
active action
Prior art date
Application number
EA201692031A
Other languages
English (en)
Inventor
Стефан Миллер
Ивз Бриерс
Роб Лавигне
Original Assignee
Лисандо Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50439296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692031(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Лисандо Аг filed Critical Лисандо Аг
Publication of EA201692031A1 publication Critical patent/EA201692031A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01028—N-Acetylmuramoyl-L-alanine amidase (3.5.1.28)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Заявленное изобретение относится к полипептиду, содержащему гидролазу пептидогликана, для применения в качестве лекарственного препарата в лечении хронических бактериальных инфекций. Заявленное изобретение также относится к полипептиду, содержащему гидролазу пептидогликана, включающую эндопептидазу, N-ацетил-мурамоил-L-аланин-амидазу, N-ацетил-мурамидазу, N-ацетил-глюкозаминидазу и/или литическую трансгликозилазу.
EA201692031A 2014-04-08 2015-04-08 Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций EA201692031A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14163927 2014-04-08
PCT/EP2015/057625 WO2015155244A1 (en) 2014-04-08 2015-04-08 Pharmaceutical composition against chronic bacterial infections

Publications (1)

Publication Number Publication Date
EA201692031A1 true EA201692031A1 (ru) 2017-07-31

Family

ID=50439296

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692031A EA201692031A1 (ru) 2014-04-08 2015-04-08 Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций

Country Status (6)

Country Link
US (1) US20170106058A1 (ru)
EP (1) EP3129044B1 (ru)
AU (1) AU2015243359B2 (ru)
CA (1) CA2941426C (ru)
EA (1) EA201692031A1 (ru)
WO (1) WO2015155244A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201692031A1 (ru) 2014-04-08 2017-07-31 Лисандо Аг Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций
WO2017186942A1 (en) * 2016-04-28 2017-11-02 Lysando Ag Antimicrobial agents against salmonella bacteria
WO2017203471A1 (en) 2016-05-27 2017-11-30 Sasinapas Co., Ltd. Endolysin variant
CN106701690A (zh) * 2016-12-13 2017-05-24 上海交通大学医学院 鲍曼不动杆菌噬菌体SH‑Ab15519及其应用
CN107298707B (zh) * 2017-07-31 2020-05-08 河南科技学院 一种类Bac5抗菌肽及其应用
US11918611B2 (en) 2018-05-03 2024-03-05 Crigasseni Ag Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of diarrheal and other microbial diseases
WO2019211643A1 (en) * 2018-05-04 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating gram positive bacterial infection
AU2019276253A1 (en) 2018-05-30 2020-11-26 Lysando Ag Novel antimicrobial proteins
US20210198645A1 (en) * 2018-05-30 2021-07-01 Lysando Ag Novel antimicrobial fusion proteins
EP3898962A2 (en) 2018-12-21 2021-10-27 Novozymes A/S Polypeptides having peptidoglycan degrading activity and polynucleotides encoding same
GB201906653D0 (en) * 2019-05-10 2019-06-26 Cc Biotech Ltd Polypeptides for treatment of bacterial infections
CN110903404A (zh) * 2019-12-30 2020-03-24 佛山科学技术学院 一种蜂毒素-死亡素重组多肽及其应用
CN111349177B (zh) * 2020-03-13 2022-04-22 西北农林科技大学 一种融合抗菌肽cat的制备方法和应用
CN116121110A (zh) * 2022-10-28 2023-05-16 益加生物科技成都有限公司 一种抑菌和抗炎作用较强的乳酸乳球菌yj0801及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
WO2010141135A2 (en) * 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
MX360300B (es) * 2009-06-26 2018-10-29 Katholieke Univ Leuven K U Leuven R&D Agentes antimicrobianos.
SG178440A1 (en) * 2009-08-24 2012-04-27 Univ Leuven Kath New endolysin obpgplys
CN103119158B (zh) * 2010-04-27 2015-04-08 莱桑多公司 减少生物膜的方法
EP2468856A1 (en) 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
SG10202009810YA (en) 2013-07-11 2020-11-27 Micreos Human Health Bv Combination treatment for atopic dermatitis
EA201692031A1 (ru) 2014-04-08 2017-07-31 Лисандо Аг Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций

Also Published As

Publication number Publication date
EP3129044A1 (en) 2017-02-15
AU2015243359B2 (en) 2020-03-12
WO2015155244A1 (en) 2015-10-15
CA2941426A1 (en) 2015-10-15
AU2015243359A1 (en) 2016-09-15
CA2941426C (en) 2022-09-27
EP3129044B1 (en) 2022-09-07
US20170106058A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
EA201692031A1 (ru) Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций
EA201892386A1 (ru) Химерные нейротоксины
EA201890204A1 (ru) Антибактериальные соединения
EA201791866A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
CL2016002123A1 (es) Nuevo polisacárido y usos del mismo
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016017108A (es) Composiciones y metodos para el cuidado personal.
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX2017005575A (es) Formulacion farmaceutica de anticuerpos anti-tnf alfa.
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2015002897A1 (es) Inhibidores de bace1
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
CL2015002620A1 (es) Derivados piridin-4-ilo
EA201692284A1 (ru) Ниацинамид для стимуляции продуцирования антимикробных пептидов
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX2017003121A (es) Formulaciones de anticuerpos.
EA201690859A1 (ru) Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений